west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "重组人甲状旁腺激素" 1 results
  • Therapeutic Effect of Recombinant Human Parathyroid Hormone(1-34) on Primary Osteoporosis

    【摘要】 目的 观察重组人甲状旁腺激素(1-34)[rhPTH(1-34)]治疗骨质疏松症患者骨密度的疗效和安全性。 方法 采用自身前后对照临床研究,纳入2008年3-5月就诊的原发性骨质疏松症患者共39例,予rhPTH(1-34) 20 μg 1次/d皮下注射,疗程18个月。治疗期间均同时口服钙制剂600 mg/d及维生素D3 125 U/d作为基础治疗。患者治疗前采用双能X线检测腰2~4椎体(L2~4)和股骨颈骨密度(BMD)、肝肾功能、血钙、血磷,治疗后6、12、18个月复查BMD和上述生化指标改变,记录患者不良事件,对患者治疗前后L2~4、股骨颈BMD变化进行对比分析。 结果 35例患者完成全疗程治疗,其中男2例,女33例;平均年龄65岁,平均病程6.5年;治疗6、12、18个月时L2~4 BMD均较治疗前明显提高(Plt;0.01),而股骨颈BMD在治疗6、12个月时改善不明显(Pgt;0.05),18个月时表现出较治疗前明显增加(Plt;0.01);腰椎平均BMD增长率为12.27%,股骨颈BMD增长率为4.11%;治疗期间不良反应少,均不需特殊处理而自行好转。 结论 rhPTH(1-34)治疗原发性骨质疏松症安全有效,对改善椎体BMD疗效迅速明显,对改善股骨颈BMD起效慢;适用于绝经后骨质疏松和老年性骨质疏松症患者。【Abstract】 Objective To observe the therapeutic effect of recombinant human parathyroid hormone (1-34) [rhPTH(1-34)] on the improvement of bone mineral density (BMD) in patients with primary osteoporosis. Methods A before and after self control study was performed on 39 patients with primary osteoporosis from March to May 2008. The patients underwent the subcutaneous injection with rhPTH (1-34) 20 μg/d for 18 months. All patients were given oral calcium (Ca 600 mg+Vit D3 125 U per day) as primary drug treatment. BMD of lumbar spine (L2-L4) and femur neck, serum calcium, and serum phosphate were measured before and 6, 12, and 18 months after the treatment. All of the adverse reactions were recorded. Results A total of 35 patients finished the trial,including two males and 33 females with the average age of 65 years and the course of disease of (6.54±4.30) years. BMD of lumbar spine (L2-L4) significantly increased 6, 12, and 18 months after treatment (Plt;0.01). There was no significant difference of femur neck BMD 6 and 12 months after treatment (Pgt;0.05), whereas by the end of the treatment, it improved significantly (Plt;0.01). The average increase rate was 12.27% in lumbar spine (L2-L4) and was 4.11% in femur neck BMD. There were a few adverse reactions during the therapeutic process, most of which were tolerable and self-restored. Conclusion rhPTH(1-34) is an effective and safe drug in treating primary osteoporosis. It can increase lumbar spine BMD rapidly and raise femur neck BMD gradually. It is applicable for postmenopausal osteoporosis and senile osteoporosis.

    Release date:2016-09-08 09:51 Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content